Ask AI
Heart Failure and MRA FINEARTS-HF
Heart Failure and MRAs: Diving Deep Into the Pivotal FINEARTS-HF Trial 

Released: June 19, 2025

Expiration: June 18, 2026

Activity

Progress
1
Course Completed

In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:

  • The emerging role of mineralocorticoid receptor antagonists in HF care
  • Finerenone’s efficacy in reducing composite cardiovascular death and worsening HF events
  • Why safety must be monitored, especially considering hyperkalemia risk
  • Where HF guideline recommendations lack compared with the current evidence